The resurgence of covalent drugs

  title={The resurgence of covalent drugs},
  author={Juswinder Singh and Russell C. Petter and Thomas A. Baillie and Adrian Whitty},
  journal={Nature Reviews Drug Discovery},
Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project. There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium. This Review surveys the prevalence and pharmacological advantages of… 

10 years into the resurgence of covalent drugs.

An overview of the milestones hit with targeted covalent inhibitors, as well as the promise and the needs of current research, are presented and many questions remain unexplored in this branch of precision medicine.

The Ascension of Targeted Covalent Inhibitors.

This Perspective will highlight the clinical and financial success of this class of drugs and provide early insight into toxicity, a key factor that had hindered progress in the field.

Covalent Inhibition in Drug Discovery

This review surveys enzymes that can be targeted by covalent inhibitors for the treatment of human diseases, focusing on protein kinases, RAS proteins, and a few other enzymes that have been studied extensively as targets for covalents.

Recent advances in the development of covalent inhibitors.

The purpose of this focused review is to provide an understanding of the development of covalent inhibitors by describing their inherent characteristics, possibilities, and limitations based on their mechanistic differences from noncovalent inhibitor.

Covalent binders in drug discovery.

Drug discovery for a new generation of covalent drugs

The review examines potential reason(s) for the excellent safety record of marketed covalent agents and advanced clinical candidates for emerging therapeutic targets and significant emphasis is placed on proteomic techniques and chemical/biochemical reactivity assays that aim to provide a systematic rank ordering of pharmacologic selectivity relative to off-target protein reactivity of covalents.

Structure-based design of targeted covalent inhibitors.

This tutorial review introduces the broader concept of covalent inhibition, discusses the potential benefits and challenges of such an approach, and provides an overview of the current status of the field.



Targeted covalent drugs of the kinase family.

Strategies for discovering and derisking covalent, irreversible enzyme inhibitors.

This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid


1. Painstaking progress in drug development is well illustrated by 5‐fluorouracil (5FU), originally designed 40 years ago as a fluorinated analogue of the naturally occurring base uracil. Innovative

Drug-target residence time: critical information for lead optimization.

  • Hao LuP. Tonge
  • Biology, Chemistry
    Current opinion in chemical biology
  • 2010

Minimizing metabolic activation during pharmaceutical lead optimization: progress, knowledge gaps and future directions.

The approaches that are currently available for addressing this issue during the lead optimization phase of drug discovery, their limitations, and future scientific directions that have the potential to address these limitations are discussed.

Drug–target residence time and its implications for lead optimization

The potential advantages of long residence time in terms of duration of pharmacological effect and target selectivity are described and the estimated dissociative half-life of the drug-target binary complex is described.

Targeting proteases: successes, failures and future prospects

  • B. Turk
  • Biology, Chemistry
    Nature Reviews Drug Discovery
  • 2006
The status of human protease research and prospects for future protease-targeted drugs are reviewed, with reference to some key examples where protease drugs have succeeded or failed.

Mechanistic basis of enzyme-targeted drugs.

The variety of inhibition mechanisms for enzyme-targeted drugs are reviewed, an enzyme target database for drugs currently marketed in the United States is established, and advanced methods for determining transition-state structure now offer the opportunity for direct drug design without resorting to expensive random testing campaigns.

Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology.

  • T. Baillie
  • Chemistry, Biology
    Chemical research in toxicology
  • 2006
Research leading to a deeper insight into mechanistic aspects of toxicities caused by reactive drug metabolites will aid greatly in the rational design of drug candidates with superior safety profiles and represents a challenging and exciting opportunity for chemical toxicology.

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.

This review will examine the evolution of covalent inhibitors of the HCV NS3.4A protease from early aldehyde molecules to alpha-ketoamide inhibitors and the pre-clinical profile and early clinical data of VX-950 will be discussed in this review.